Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma
Conditions
Brief summary
This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not yet known whether MRI with gadoxetate disodium provides a more precise measurement of liver tumors than standard computed tomography (CT).
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the precision of gadoxetate (gadoxetate disodium)-enhanced MRI in evaluating lesion size. II. To evaluate if there is a subjective improvement in the delineation of hepatocellular carcinoma (HCC) in the hepatocellular phase of contrast administration. III. To further assess the sensitivity of gadoxetate-enhanced MRI for the detection of HCC. SECONDARY OBJECTIVES: I. To evaluate the reproducibility of various tumor measurement techniques in the evaluation of HCC. II. To further evaluate how administration of gadoxetate affects diffusion weighted imaging. OUTLINE: Patients receive gadoxetate disodium intravenously (IV) and then undergo enhanced liver MRI. After completion of study, patients are followed up at 2, 4, 8, and 12 months.
Interventions
Given IV
DEVICEMagnetic Resonance Imaging
Undergo MRI with gadoxetate disodium
Sponsors
National Cancer Institute (NCI)
University of Southern California
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* CT features suggestive of HCC, including those features which have been described herein; they are also enumerated below: * For an arterially-enhancing lesion greater than or equal to 1 cm, but under 2 cm, all of the following criteria must be met: * Imaging features of a mass * Wash-out on later phases of contrast administration * At least 1 cm or more growth * For an arterially-enhancing lesion greater than or equal to 2 cm, two of the following criteria must be met: * Imaging features of a mass * Wash-out on later phases of contrast administration * At least 1 cm or more growth * All enhancing lesions with expansile, solid, enhancing tumor within vascular structures will be included, including the main portal vein, the main right and main left portal veins, the inferior vena cava (IVC), and the main hepatic veins * No prior history of treatment of liver lesions * Able to provide written and verbal informed consent * Able to tolerate a complete abdominal MR examination, within 3 weeks of CT
Exclusion criteria
* Unable to provide written and verbal informed consent * Unable to undergo MRI due to intraocular metallic foreign body, pacemaker, or other contraindications including objects in the body which are deemed to be unsafe or notable to be assessed, or unable to undergo MRI within 3 weeks of CT * Pregnancy * Severe renal insufficiency as defined by an estimated glomerular filtration rate of less than 30 cc/minute * Severe liver disease as defined by Childs class C cirrhosis * History of a previous reaction to contrast media * History of bronchial asthma * History of allergic disorders * Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring size (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability | Up to 24 hours | Initially, a random effects analysis of variance (ANOVA) will be performed for each type of image (CT vs. MRI), for each phase (4 for CT and 5 for MRI) and for each method of measuring size (1-, 2-, and 3-dimensional) - for a total of 27 ANOVAs. Lesion, radiologist, and replication (for the 20 target lesions measured twice) will all be random effects; the inter-reader and the intra-reader variability will be estimated from these models and 95% confidence intervals will be constructed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate | Up to 24 hours | ADC values will be recorded for uninvolved liver parenchyma and for tumors before and after administration of gadoxetate disodium. |
Countries
United States
Outcome results
None listed